Tissue Regenix Group PLC Additional Director Disclosures (3465B)

TIDMTRX

RNS Number : 3465B

Tissue Regenix Group PLC

10 February 2022

Tissue Regenix Group plc

("Tissue Regenix" or "the Group")

Additional Director Disclosures

Tissue Regenix Group (AIM:TRX), the regenerative medical devices company, announces the following additional disclosures under Schedule 2(g) of the AIM Rules for Companies relating to Brian Phillips, Non-Executive Director. These are in addition to those details already announced on 5 January 2021.

Mr Phillips' career in private equity resulted in him holding a number of non-executive directorship positions in respect of his firm's investee companies, including the following: Diamond Group Holdings Public Limited Company to which a receiver was appointed in 1992; Mr Phillips was a director of group companies, The Allen Partnership Limited and Public House Holdings Limited, when an administration order was made on both companies in October 1992; Cannock Group Limited went into voluntary creditors' liquidation in December 1998 while Mr Phillips was a director; and a receiver was appointed in respect of the administration of Alma Holdings Limited in February 1992 while Mr Phillips was a director.

For more information:

 
 Tissue Regenix Group plc                                    www.tissueregenix.com 
  David Cocke, Chief Financial Officer                             Via Walbrook PR 
 
 Stifel Nicolaus Europe Limited (Nominated Adviser         Tel: +44(0)20 7710 7600 
  and Broker) 
  Ben Maddison / Alex Price 
 Walbrook PR Ltd                                          Tel: +44 (0)20 7933 8780 
  Alice Woodings / Lianne Applegarth                  TissueRegenix@walbrookpr.com

About Tissue Regenix (www.tissuergenix.com)

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL(R)') technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or worn out body parts. Current applications address many critical clinical needs such as sports medicine, heart valve replacement and wound care.

In August 2017 Tissue Regenix acquired CellRight Technologies(R), a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and wound care scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopaedic, foot & ankle, dental, and sports medicine surgical procedures.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RDNUROVRUOUUAAR

(END) Dow Jones Newswires

February 10, 2022 10:44 ET (15:44 GMT)

Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Jun 2024 to Jul 2024